← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
mosunetuzumab
L01FX25
Forms & Strengths
- Intravenous solution: 1 mg/1 mL single-dose vial
- Intravenous solution: 30 mg/30 mL single-dose vial
Adult Dosing
- Cycle 1 Day 1: 1 mg IV
- Cycle 1 Day 8: 2 mg IV
- Cycle 1 Day 15: 60 mg IV
- Cycle 2-8 Day 1: 60 mg IV every 21 days
- Premedicate with corticosteroid, antihistamine, and antipyretic prior to each dose in Cycle 1
Pediatric Dosing
- Safety and efficacy have not been established in pediatric patients
Indications
- Relapsed or refractory follicular lymphoma after at least two prior lines of systemic therapy
Mechanism of Action
- CD20xCD3 T-cell engaging bispecific monoclonal antibody
- Binds to CD20 on B-cells and CD3 on T-cells
- Mediates T-cell activation and subsequent lysis of malignant B-cells
Contraindications
- Hypersensitivity to mosunetuzumab or any of its excipients
Adverse Reactions
- Cytokine Release Syndrome (CRS)
- Neurologic toxicity including ICANS
- Fatigue and pyrexia
- Rash and musculoskeletal pain
- Neutropenia, anemia, and thrombocytopenia
- Serious infections
Drug Interactions
- Live vaccines: Avoid concomitant use due to immunosuppression
- Strong CYP450 inducers/inhibitors: No formal dedicated PK studies, but transient cytokine release during Cycle 1 may alter CYP450 enzyme activity
Curated Content: Needs Vetting Before Put to Clinical Use